RNN’s Phase 2a results have analyst optimistic on RX-3117 drug for patients running out of options.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced its founder, Chang Ahn, Ph.
Rexahn Strengthens Patent Portfolio Through Newly Issued Patent for Cancer Drug
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced financial results for the second quarter ended June 30, 2017 and provided an update on the Company’s clinical …
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced that the U.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced it has entered into definitive agreements with institutional investors to purchase approximately 3.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) offered a key glimpse into its advanced muscle invasive bladder cancer (MIBC) Phase 2a trial at the American Society …
FBR analyst Vernon Bernardino, one of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) biggest bulls, is slashing the price target for the drug maker to $14.
H.C.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced financial results for the first quarter ended March 31, 2017 and provided an update on the Company’s clinical …
